Clinical trial/clinical trial/Vertex Pharmaceuticals

Zimislecel (VX-880)

This is one of the most advanced cell-replacement programs and has reported trial participants reducing or eliminating injected insulin. It still depends on lifelong immunosuppression, which is the trade-off researchers are now trying to remove.

How it works

Fully differentiated, insulin-producing islet cells made from stem cells are infused into the liver's portal vein. Because the cells are donor-derived, recipients take immune-suppressing medicine to protect them.

Approach
Stem cell-derived islet cell therapy
Immunosuppression
Requires chronic immunosuppression

Live trial status

NCT04786262RECRUITING

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Phase: PHASE3Enrollment: 52Updated: Mar 16, 2026
Open ClinicalTrials.gov record

These are research programs pursuing a functional cure or disease modification for type 1 diabetes. None is a confirmed, broadly available cure. Trial status is informational, not medical advice, and not a recruiting offer. Verify eligibility and details with the official trial record and a clinician.

Family-tested T1D gear

Some links below are affiliate links. If you buy through them, Type1Cure may earn a small commission at no extra cost to you. Affiliate relationships never affect our research coverage, evidence labels, rankings, or safety alerts.